Endocan expression and localization in human glioblastomas

Journal of Neuropathology and Experimental Neurology

Volumn 68, Issue 6, 2009, Pages 633-641

  Maurage, Claude Alain ^a,b   Adam, Estelle ^c   Minéo, Jean Francois ^d   Sarrazin, Stéphane ^e   Debunne, Manuelle ^c   Siminski, Rose Mary ^a   Baroncini, Marc ^a,d   Lassalle, Philippe ^c   Blond, Serge ^a,d   Delehedde, Maryse ^c  

^a INSERM   (France)

^b Centre Hospitalier Régional Universitaire   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e INSTITUT DE BIOLOGIE STRUCTURALE   (France)

Author keywords

Angiogenesis; Endocan; Endothelial; FGF 2; Glioblastoma; Hypoxia

Indexed keywords

COBALT CHLORIDE; ENDOCAN; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR 1; PROTEOGLYCAN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ESM1 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BRAIN CORTEX; CELL LINE; CELL VIABILITY; ENDOTHELIUM CELL; ENZYME SYNTHESIS; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPLASIA; HYPOXIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; SURVIVAL RATE; TUMOR CELL; UPREGULATION; ANOXIA; BRAIN TUMOR; CLASSIFICATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SURVIVAL; TIME; TUMOR CELL LINE;

ADULT; AGED; ANOXIA; BRAIN NEOPLASMS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOGLYCANS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649413407     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181a52a7f     Document Type: Article

References (50)

1. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol Mech Dis 2006;1:97-117
2. Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumours of the Central Nervous System, Vol 1. 4th ed. Lyon: IARC Press, 2007
3. Simpson L, Galanis E. Recurrent glioblastoma multiforme: Advances in treatment and promising drug candidates. Expert Rev Anticancer Ther 2006;6:1593-1607
4. Mineo JF, Bordron A, Baroncini M, et al. Prognosis factors of survival time in patients with glioblastoma multiforme: A multivariate analysis of 340 patients. Acta Neurochir 2007;2:2
5. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 2005;109:93-108
6. Fischer I, Gagner JP, Law M, et al. Angiogenesis in gliomas: Biology and molecular pathophysiology. Brain Pathol 2005;15:297-310
7. Jansen M, de Witt Hamer PC, Witmer AN, et al. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Brain Res Rev 2004;45:143-163
8. Bogler O, Mikkelsen T. Angiogenesis and apoptosis in glioma: Two arenas for promising new therapies. J Cell Biochem 2005;96:16-24
9. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cellYspecific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458-20464
10. Bechard D, Gentina T, Delehedde M, et al. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepato-cyte growth factor/scatter factor mitogenic activity. J Biol Chem 2001; 276:48341-48349
11. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006;1765:25-37
12. Bechard D, Meignin V, Scherpereel A, et al. Characterization of the secreted form of endothelial-cellYspecific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000;37:417-425
13. Tsai JC, Zhang J, Minami T, et al. Cloning and characterization of the human lung endothelial-cellYspecific molecule-1 promoter. J Vasc Res 2002;39:148-159
14. Aitkenhead M, Wang SJ, Nakatsu MN, et al. Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: Induction of ESM-1, (beta)ig-h3, and NrCAM. Microvasc Res 2002;63:159-171
15. Grigoriu BD, Depontieu F, Scherpereel A, et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 2006;12:4575-4582
16. Gerritsen ME, Tomlinson JE, Zlot C, et al. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 2003;140:595-610
17. Amatschek S, Koenig U, Auer H, et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 2004;64:844-856
18. Schoenfeld J, Lessan K, Johnson NA, et al. Bioinformatic analysis of primary endothelial cell gene array data illustrated by the analysis of transcriptome changes in endothelial cells exposed to VEGF-A and PIGF. Angiogenesis 2004;7:143-156
19. Abid MR, Yi X, Yano K, et al. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 2006;72:136-145
20. Van t predicts clinical outcome of breast cancer. Nature 2002;415:530-536
21. Lenburg ME, Liou LS, Gerry NP, et al. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 2003;3:31
22. Wellner M, Herse F, Janke J, et al. Endothelial cell specific molecule-1Va newly identified protein in adipocytes. Horm Metab Res 2003;35: 217-221
23. Seftor EA, Meltzer PS, Schatteman GC, et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: Role in vasculogenic mimicry. Crit Rev Oncol Hematol 2002;44:17-27
24. Hendrix MJ, Seftor EA, Hess AR, et al. Molecular plasticity of human melanoma cells. Oncogene 2003;22:3070-3075
25. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-235
26. Kirwan RP, Leonard MO, Murphy M, et al. Transforming growth factor-betaYregulated gene transcription and protein expression in human GFAP-negative lamina cribrosa cells. Glia 2005;52:309-324
27. Sarrazin S, Bonnaffe D, Lubineau A, et al. Heparan sulfate mimicry: A synthetic glycoconjugate that recognizes the heparin binding domain of interferon-gamma inhibits the cytokine activity. J Biol Chem 2005;280: 37558-37564
28. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
29. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncol 2005;7:436-451
30. Rempel SA, Dudas S, Ge S, et al. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 2000;6:102-111
31. Hardwick JS, Yang Y, Zhang C, et al. Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling. Mol Cancer Ther 2005;4:413-425
32. Huang GW, Tao YM, Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 2009;54: 389-394
33. Rak J, Yu JL, Luyendyk J, et al. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006;66:10643-10646
34. Rong Y, Durden DL, Van Meir EG, et al. FPseudopalisading-necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006;65: 529-539
35. Belting M,Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005;25:1545-1550
36. Roessler K, Suchanek G, Breitschopf H, et al. Detection of tumor necrosis factor-alpha protein and messenger RNA in human glial brain tumors: Comparison of immunohistochemistry with in situ hybridization using molecular probes. J Neurosurg 1995;83:291-297
37. Gross JL, Morrison RS, Eidsvoog K, et al. Basic fibroblast growth factor: A potential autocrine regulator of human glioma cell growth. J Neurosci Res 1990;27:689-696
38. Takahashi JA, Mori H, Fukumoto M, et al. Gene expression of fibroblast growth factors in human gliomas and meningiomas: Demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci U S A 1990;87:5710-5714
39. Zagzag D, Miller DC, Sato Y, et al. Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res 1990;50: 7393-7398
40. Morrison RS. Suppression of basic fibroblast growth factor expression by antisense oligodeoxynucleotides inhibits the growth of transformed human astrocytes. J Biol Chem 1991;266:728-734
41. Auguste P, Gursel DB, Lemiere S, et al. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res 2001;61:1717-1726
42. Borczuk AC, Shah L, Pearson GD, et al. Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med 2004;170:167-174
43. Scherpereel A, Gentina T, Grigoriu B, et al. Overexpression of endocan induces tumor formation. Cancer Res 2003;63:6084-6089
44. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106
45. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2:306-314
46. Laird AD, Vajkoczy P, Shawver LK, et al. SU6668 is a potent anti-angiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000;60:4152-4160
47. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61:6624-6628
48. Goldbrunner RH, Bendszus M, Wood J, et al. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 2004;55: 426-432
49. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-974
50. Zagzag D, Lukyanov Y, Lan L, et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: Implications for angio-genesis and glioma cell invasion. Lab Invest 2006;86:1221-32